Curaleaf Rebuts Aurora's 'Deflection' on Shareholder Value Claims
MSO fires back at Aurora Cannabis, saying Canadian rival is dodging the core question of returns.
Diverse group of professionals in a formal meeting setting with a speaker at the podium.
Curaleaf Escalates Rhetoric in Takeover Fight
Curaleaf accused Aurora Cannabis of deflecting from shareholder value creation in a statement issued August 25. The MSO's response came after Aurora released its own defense of management performance, a move Curaleaf characterized as sidestepping the core metric: total shareholder return over the past three years.
Curaleaf's thesis is straightforward. Aurora's stock has lagged both the North American Cannabis Operator Index and peer LPs since 2023. The company's pivot from cultivation scale to branded consumer products hasn't translated into margin expansion. That math is hard to argue with.
The statement didn't specify which Aurora filing or press release prompted the rebuttal, but the timing aligns with Aurora's Q4 2026 earnings call last week. CEO Miguel Martin emphasized international medical revenue growth and cost discipline. Curaleaf evidently sees that narrative as incomplete.
The Shareholder-Return Gap Aurora Can't Close
Aurora's three-year total shareholder return trails Curaleaf's by an estimated 47 percentage points, according to Curaleaf's investor presentation filed in July. The gap widens when adjusted for currency headwinds and dilution from Aurora's 2024 equity raise.
Key performance divergences include:
- Revenue growth: Curaleaf's U.S. retail footprint grew 18% year-over-year in Q2 2026; Aurora's medical sales grew 9%.
- EBITDA margin: Curaleaf posted 22% adjusted EBITDA margin in Q2; Aurora reported 14%.
- Cash burn: Aurora used CA$31 million in operating cash in Q4 2025; Curaleaf generated US$47 million in the same quarter.
Aurora's counter-argument has centered on its international optionality and federal-legalization upside. Curaleaf's rebuttal suggests those talking points aren't resonating with proxy advisors. ISS and Glass Lewis have yet to issue recommendations on Curaleaf's offer, which remains on the table at 0.375 Curaleaf shares per Aurora share.
What Happens Next in the Proxy Fight
The next milestone is Aurora's special shareholder meeting, tentatively scheduled for late September. Curaleaf needs 66.7% of votes cast to approve the transaction under Canadian takeover rules. That's a high bar in a contested deal.
Aurora's board has recommended shareholders reject the offer. The company has until September 10 to file a formal defense circular with the Ontario Securities Commission. Curaleaf's August 25 statement reads like a preemptive strike ahead of that filing, framing Aurora's defense as evasion rather than substance.
For more background on the Curaleaf-Aurora battle, see the CannIntel topic hub on the Curaleaf-Aurora takeover fight.
The political variable nobody can model is whether federal cannabis reform in the U.S. arrives before Aurora's shareholders vote. If Schedule III rescheduling becomes effective in Q4 2026, Curaleaf's valuation advantage narrows and Aurora's "wait-and-see" strategy gains credibility. If not, the value gap speaks for itself.
Frequently asked questions
What is Curaleaf's takeover offer for Aurora Cannabis?
Curaleaf has offered 0.375 Curaleaf shares per Aurora share, valuing Aurora at approximately US$2.3 billion based on Curaleaf's August 2026 trading price. The offer requires 66.7% shareholder approval under Canadian takeover rules.
Why does Curaleaf say Aurora is deflecting on shareholder value?
Curaleaf argues Aurora's management has focused on narrative themes like international expansion and cost discipline while avoiding direct discussion of total shareholder return, where Aurora has underperformed Curaleaf and peer LPs by double digits over three years.
When will Aurora shareholders vote on Curaleaf's offer?
Aurora's special shareholder meeting is tentatively scheduled for late September 2026. Aurora's board has recommended shareholders reject the offer, and the company must file a formal defense circular by September 10.
How do Curaleaf and Aurora's financials compare?
In Q2 2026, Curaleaf reported 22% adjusted EBITDA margin and US$47 million in operating cash generation, while Aurora posted 14% EBITDA margin and burned CA$31 million in operating cash in Q4 2025.
What could change the outcome of the Aurora takeover vote?
If DEA Schedule III rescheduling becomes effective before the vote, Curaleaf's valuation advantage narrows and Aurora's argument for remaining independent gains weight. Proxy advisor recommendations from ISS and Glass Lewis will also be decisive.
Sources
The cannabis newsletter you forward to your team.
Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.
No spam. Unsubscribe with one click. 21+ only.
Related from Business
Tilray Medical Wins Approval for In-House EU-GMP Cannabis Testing
Tilray Medical can now run EU-GMP quality testing in-house, a move that could shift lab costs and batch-release timing, though key details remain undisclosed.
Canopy Growth Secures EU-GMP Certification at Smiths Falls
Canopy Growth's Smiths Falls site is now certified for softgel manufacturing and primary packaging of softgels, oral liquids and dried flower, extending its EU-GMP supply chain.
INFARMED Approves Tilray Medical's In-House EU-GMP Testing in Portugal
Portugal's medicines regulator cleared Tilray Medical to run quality-control testing at its own Portuguese site, a step aimed at speeding product releases into regulated markets.
More from the newsroom
County Commissioners Vote for Cannabis Moratorium, Herald Reports
A county board voted to pause new cannabis operations, the Austin Daily Herald reported, adding to Minnesota's patchwork of local rules under the 2023 adult-use law.
Ex-DEA Official Warns Against Schedule III Licenses Before Court Rules
A former senior DEA official urged that Schedule III marijuana licenses wait for a federal appeals court ruling, raising a sequencing question for operators and investors.
South Dakota AG Says Rescheduling Has 'Negligible Impact' on Medical Program
South Dakota's attorney general says a federal Schedule III move barely touches the state's voter-approved medical marijuana program, leaving 280E relief as the main operator-level change.